Demographics and clinical characteristics of the newly diagnosed AML patients in the study set
| Treated . | Category . | All cases . | All treated cases . | Lowest third . | Middle third . | Highest third . | P . |
|---|---|---|---|---|---|---|---|
| N | 511 | 415 | 147 | 131 | 137 | ||
| Male/female | 291:220 | 218:197 | 73:56 | 71:70 | 75:69 | .79 | |
| Age, y | Minimum | 15.8 | 15.8 | 17.4 | 17.3 | 15.8 | |
| Maximum | 87.23 | 87.4 | 87.4 | 83.4 | 85.8 | .33 | |
| Median | 65.7 | 64.3 | 61.9 | 64.5 | 65.5 | ||
| FAB | M0 | 5.7% | 5.1% | 8.2% | 3.8% | 2.9% | .09 |
| M1 | 10.8% | 11.6% | 10.2% | 16.0% | 8.8% | .14 | |
| M2 | 33.1% | 36.9% | 47.6% | 34.4% | 27.7% | .002 | |
| M4 | 22.7% | 23.4% | 12.2% | 21.4% | 37.2% | .000003 | |
| M5 | 10.0% | 9.9% | 10.2% | 9.2% | 10.2% | .95 | |
| M6 | 5.3% | 5.1% | 4.1% | 7.6% | 3.6% | .24 | |
| M7 | 2.0% | 1.9% | 3.4% | 0.8% | 1.5% | .25 | |
| Unknown | 7.2% | 5.5% | 4.1% | 6.1% | 6.6% | .62 | |
| RAEBT | 3.3% | 0.7% | 0.0% | 0.8% | 1.5% | ||
| Cytogenetics | Favorable | 6.7% | 8.0% | 11.6% | 6.1% | 5.8% | |
| Intermediate | 44.0% | 47.0% | 48.3% | 41.2% | 51.1% | .11 | |
| Unfavorable | 49.3% | 45.1% | 40.1% | 52.7% | 43.1% | ||
| FLT-3 | ITD | 14.9% | 17.8% | 17.7% | 20.6% | 15.3% | .74 |
| D835 | 3.1% | 5.8% | 6.8% | 5.3% | 5.1% | .96 | |
| Both | 1.6% | 1.9% | 2.0% | 1.5% | 2.2% | .8 | |
| Zubrod PS | 3 or 4 | 3.3% | 3.1% | 2.0% | 1.5% | 5.8% | .15 |
| AHD | ≥ 2 months | 39.9% | 37.1% | 32.7% | 38.2% | 40.9% | .39 |
| Infection | Yes | 19.8% | 22.2% | 23.1% | 21.4% | 21.9% | .94 |
| WBCs | Median | 8.8 | 9.9 | 13.3 | 9.9 | 8.8 | .48 |
| Platelets | Median | 56 | 55.5 | 49 | 65 | 56 | .26 |
| Hemoglobin | Median | 9.6 | 9.6 | 9.8 | 9.7 | 9.2 | .23 |
| % BM blast | Median | 46 | 50 | 58 | 45 | 47 | .06 |
| % Blood blast | Median | 18 | 20.5 | 35 | 16 | 12 | .000002 |
| Response | CR | 57.1% | 55.1% | 65.6% | 51.1% | .045 | |
| Resistant | 32.8% | 36.1% | 23.7% | 38.0% | .026 | ||
| Fail | 10.1% | 8.8% | 10.7% | 10.9% | .81 | ||
| Relapse | 61.6% | 45.7% | 67.4% | 72.9% | .001 | ||
| Alive | 25.8% | 34.0% | 28.2% | 14.6% | .001 | ||
| Overall survival, wk (median) | 49.14 | 53.9 | 61.6 | 38.9 | .0015 | ||
| Remission duration, wk (median) | 45.86 | 97.6 | 44.7 | 31.1 | .0007 | ||
| Treated . | Category . | All cases . | All treated cases . | Lowest third . | Middle third . | Highest third . | P . |
|---|---|---|---|---|---|---|---|
| N | 511 | 415 | 147 | 131 | 137 | ||
| Male/female | 291:220 | 218:197 | 73:56 | 71:70 | 75:69 | .79 | |
| Age, y | Minimum | 15.8 | 15.8 | 17.4 | 17.3 | 15.8 | |
| Maximum | 87.23 | 87.4 | 87.4 | 83.4 | 85.8 | .33 | |
| Median | 65.7 | 64.3 | 61.9 | 64.5 | 65.5 | ||
| FAB | M0 | 5.7% | 5.1% | 8.2% | 3.8% | 2.9% | .09 |
| M1 | 10.8% | 11.6% | 10.2% | 16.0% | 8.8% | .14 | |
| M2 | 33.1% | 36.9% | 47.6% | 34.4% | 27.7% | .002 | |
| M4 | 22.7% | 23.4% | 12.2% | 21.4% | 37.2% | .000003 | |
| M5 | 10.0% | 9.9% | 10.2% | 9.2% | 10.2% | .95 | |
| M6 | 5.3% | 5.1% | 4.1% | 7.6% | 3.6% | .24 | |
| M7 | 2.0% | 1.9% | 3.4% | 0.8% | 1.5% | .25 | |
| Unknown | 7.2% | 5.5% | 4.1% | 6.1% | 6.6% | .62 | |
| RAEBT | 3.3% | 0.7% | 0.0% | 0.8% | 1.5% | ||
| Cytogenetics | Favorable | 6.7% | 8.0% | 11.6% | 6.1% | 5.8% | |
| Intermediate | 44.0% | 47.0% | 48.3% | 41.2% | 51.1% | .11 | |
| Unfavorable | 49.3% | 45.1% | 40.1% | 52.7% | 43.1% | ||
| FLT-3 | ITD | 14.9% | 17.8% | 17.7% | 20.6% | 15.3% | .74 |
| D835 | 3.1% | 5.8% | 6.8% | 5.3% | 5.1% | .96 | |
| Both | 1.6% | 1.9% | 2.0% | 1.5% | 2.2% | .8 | |
| Zubrod PS | 3 or 4 | 3.3% | 3.1% | 2.0% | 1.5% | 5.8% | .15 |
| AHD | ≥ 2 months | 39.9% | 37.1% | 32.7% | 38.2% | 40.9% | .39 |
| Infection | Yes | 19.8% | 22.2% | 23.1% | 21.4% | 21.9% | .94 |
| WBCs | Median | 8.8 | 9.9 | 13.3 | 9.9 | 8.8 | .48 |
| Platelets | Median | 56 | 55.5 | 49 | 65 | 56 | .26 |
| Hemoglobin | Median | 9.6 | 9.6 | 9.8 | 9.7 | 9.2 | .23 |
| % BM blast | Median | 46 | 50 | 58 | 45 | 47 | .06 |
| % Blood blast | Median | 18 | 20.5 | 35 | 16 | 12 | .000002 |
| Response | CR | 57.1% | 55.1% | 65.6% | 51.1% | .045 | |
| Resistant | 32.8% | 36.1% | 23.7% | 38.0% | .026 | ||
| Fail | 10.1% | 8.8% | 10.7% | 10.9% | .81 | ||
| Relapse | 61.6% | 45.7% | 67.4% | 72.9% | .001 | ||
| Alive | 25.8% | 34.0% | 28.2% | 14.6% | .001 | ||
| Overall survival, wk (median) | 49.14 | 53.9 | 61.6 | 38.9 | .0015 | ||
| Remission duration, wk (median) | 45.86 | 97.6 | 44.7 | 31.1 | .0007 | ||
RAEBT indicates refractory anemia with excess of blasts in transformation; PS, Performance Status; AHD, antecedent hematologic disorder; and WBCs, white blood cells.